hotspot -WSS

hotspot

author：comprehensive 2025-09-06 02:04:22 - browse：46

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： In medicine, common shorthands can shortchange care

leisure time

WSS

Alabama IVF ruling threatens families facing fatal genetic disease

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

In utero gene editing: an explainer

6 phony surgeries that take placebo to the extreme

With competition flaring, obesity drug hits goal in liver disease study

entertainment

hotspot

hotspot

Bright Health sells Medicare Advantage business to Molina

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Dobbs anniversary: the lost opportunity of abortion as health care

NIH study of ME/CFS points to clear biological hallmarks

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

State Dept. review finds Biden bears some blame for Afghanistan failures

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Continuity nursing helped my family in our darkest PICU moments

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

entertainment

Alabama hospital puts IVF treatments on hold

Obesity drugs seen as possible treatment for liver disease MASH

New documents shed light on MD Anderson Cancer Institute feud

Mississippi candidates for statewide offices square off in party primaries

Alabama frozen embryo ruling has major implications for IVF clinics

The Harvard botanist who searched for psychedelics in the Amazon

leisure time

leisure time

entertainment

focus